BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Clinical Outcome
7 results:

  • 1. bap1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
    Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
    Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
    Huang Y; Wang J; Jia P; Li X; Pei G; Wang C; Fang X; Zhao Z; Cai Z; Yi X; Wu S; Zhang B
    Nat Commun; 2019 Mar; 10(1):1245. PubMed ID: 30886153
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, bap1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
    Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
    Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
    Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
    Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.